Thiopurines in inflammatory bowel disease: New strategies for optimization of pharmacotherapy?

Current Gastroenterology Reports

Volumn 8, Issue 2, 2006, Pages 89-92

  Derijks, Luc J J ^a   Hommes, Daniel W ^b  

^a MÁXIMA MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

6 METHYLTHIOINOSINE; AZATHIOPRINE; INORGANIC PYROPHOSPHATASE; INOSINE TRIPHOSPHATE; MERCAPTOPURINE; THIOGUANOSINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ALLELE; BONE MARROW DISEASE; BONE MARROW SUPPRESSION; CROHN DISEASE; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; ENZYME ACTIVITY; FOLLOW UP; GENE MUTATION; GENOTYPE; HUMAN; IMMUNE DEFICIENCY; LEUKOPENIA; LIVER DISEASE; LIVER HYPERPLASIA; NOTE; PANCYTOPENIA; PATIENT COMPLIANCE; PORTAL HYPERTENSION; PREDICTION; REMISSION; TREATMENT OUTCOME;

ANTIMETABOLITES; AZATHIOPRINE; DRUG MONITORING; GENOTYPE; HUMANS; INFLAMMATORY BOWEL DISEASES; METHYLTRANSFERASES; PYROPHOSPHATASES; THIOGUANINE;

EID: 33645538464     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-006-0001-0     Document Type: Note

References (45)

1. Adler DJ, Korelitz BI: The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 1990, 85:717-722.
2. Pearson DC, May GR, Fick GH, et al.: Azathioprine and 6-mercaptopurine in Crohn disease: A meta-analysis. Ann Intern Med 1995, 123:132-142.
3. Sandborn WJ: A review of immune modifier therapy for inflammatory bowel disease: Azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996, 91:423-433.
4. Kirschner BS: Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998, 115:813-821.
5. Present DH, Meltzer SJ, Krumholz MP, et al.: 6-Mercaptopurine in the management of inflammatory bowel disease: Short- and long-term toxicity. Ann Intern Med 1989, 111:641-649.
6. Connell WR, Kamm MA, Ritchie JK, et al.: Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993, 34:1081-1085.
7. Lennard L, Singleton HJ: High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: Quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr 1992, 583:83-90.
8. Dervieux T, Boulieu R: Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem 1998, 44:551-555.
9. Erdmann GR, France LA, Bostrom BC, et al.: A reversed phase high performance liquid chromatography approach in determining total red blood cell concentrations of 6-thioguanine, 6-mercaptopurine, methylthioguanine, and methylmercaptopurine in a patient receiving thiopurine therapy. Biomed Chromatogr 1990, 4:47-51.
10. Cuffari C, Theoret Y, Latour S, et al.: 6-Mercaptopurine metabolism in Crohn's disease: Correlation with efficacy and toxicity. Gut 1996, 39:401-406.
11. Dubinsky MC, Lamothe S, Yang HY, et al.: Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, 118:705-713.
12. Cuffari C, Hunt S, Bayless T: Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001, 48:642-646.
13. Achkar JP, Stevens T, Easley K, et al.: Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004,10:339-345.
14. Hindorf U, Lyrenas E, Nilsson A, et al.: Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease. Scand J Gastroenterol 2004, 39:1105-1112.
15. Dubinsky MC, Yang H, Hassard PV, et al.: 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002, 122:904-915.
16. Belaiche J, Desager JP, Horsmans Y, et al.: Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol 2001, 36:71-76.
17. Lowry PW, Franklin CL, Weaver AL, et al.: Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001, 49:665-670.
18. Gupta P, Gokhale R, Kirschner BS: 6-mercaptopurine metabolite levels in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001, 33:450-454.
19. Goldenberg BA, Rawsthome P, Bernstein CN: The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am J Gastroenterol 2004, 99:1744-1748.
20. Sandborn WJ: 6-MP metabolite levels: A potential guide to Crohn's disease therapy. Gastroenterology 1997, 113:690-692.
21. Cohen RD: Forecast for using metabolite measurements in the dosing of azathioprine or 6-mercaptopurine for IBD patients: "partly cloudy". Gastroenterology 2002, 122:2082-2084, discussion 2084.
22. Derijks LJ, Gilissen LP, Engels LG, et al.: Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: Implications for therapy. Ther Drug Monit 2004, 26:311-318.
23. Gilissen LP, Derijks LJ, Bos LP, et al.: Some cases demonstrating the clinical usefulness of therapeutic drug monitoring in thiopurine-treated inflammatory bowel disease patients. Eur J Gastroenterol Hepatol 2004, 16:705-710.
24. Gilissen LP, Derijks LJJ, Bos LP, et al.: Therapeutic drug monitoring in patients with inflammatory bowel disease and established azathioprine therapy. Clin Drug Invest 2004, 24:479-486.
25. Ansari A, Hassan C, Duley J, et al.: Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002, 16:1743-1750.
26. Black AJ, McLeod HL, Capell HA: Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998, 129:716-718.
27. Lennard L: TPMT in the treatment of Crohn's disease with azathioprine. Gut 2002, 51:143-146.
28. Louis E, Belaiche J: Optimizing treatment with thioguanine derivatives in inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2003, 17:37-46.
29. Colombel JF, Ferrari N, Debuysere H, et al.: Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000, 118:1025-1030.
30. Marinaki AM, Ansari A, Duley JA, et al.: Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004, 14:181-187.
31. Gearry RB, Roberts RL, Barclay ML, et al.: Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics 2004, 14:779-781.
32. Allorge D, Hamdan R, Broly F, et al.: ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression. Gut 2005, 54:565.
33. Dubinsky MC, Hassard PV, Seidman EG, et al.: An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001, 7:181-189.
34. Baert F, Rutgeerts P: 6-Thioguanine: A naked bullet? (Or how pharmacogenomics can make old drugs brand new). Inflamm Bowel Dis 2001, 7:190-191.
35. Derijks LJ, De Jong DJ, Gilissen LP, et al.: 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: A short-term safety assessment. Eur J Gastroenterol Hepatol 2003, 15:63-67.
36. Dubinsky MC, Feldman EJ, Abreu MT, et al.: Thioguanine: A potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol 2003, 98:1058-1063.
37. Bonaz B, Boitard J, Marteau P, et al.: Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. Aliment Pharmacol Ther 2003, 18:401-408.
38. Lancaster DL, Patel N, Lennard L, et al.: Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia. Cancer Chemother Pharmacol 2002, 50:33-36.
39. Dervieux T, Blanco JG, Krynetski EY, et al.: Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res 2001, 61:5810-5816.
40. Herrlinger KR, Kreisel W, Schwab M, et al.: 6-thioguanine-efficacy and safety in chronic active Crohn's disease. Aliment Pharmacol Ther 2003, 17:503-508.
41. Herrlinger KR, Deibert P, Schwab M, et al.: Remission maintenance by tioguanine in chronic active Crohn's disease. Aliment Pharmacol Ther 2003, 17:1459-1464.
42. Dubinsky MC, Vasiliauskas EA, Singh H, et al.: 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003, 125:298-303.
43. Geller SA, Dubinsky MC, Poordad FF, et al.: Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am J Surg Pathol 2004, 28:1204-1211.
44. Naber AH, Van Haelst U, Yap SH: Nodular regenerative hyperpiasia of the liver: An important cause of portai hypertension in non-cirrhotic patients. J Hepatol 1991, 12:94-99.
45. Stromeyer FW, Ishak KG: Nodular transformation (nodular "regenerative" hyperplasia) of the liver: A clinicopathologic study of 30 cases. Hum Pathol 1981, 12:60-71.